

References

Chapter 43

- 1 Campbell SM, Braspenning J, Hutchinson A, Marshall A. Research methods used in developing and applying quality indicators in primary care. *Quality and Safety in Health Care*. 2002;**11**:358–64.
- 2 Hoven JL, Haaijer-Ruskamp FM, Vander Stichele RH; DURQUIM Scientific Committee. Indicators of prescribing quality in drug utilisation research: report of a European meeting (DURQUIM, 13–15 May 2004). *European Journal of Clinical Pharmacology*. 2005;**60**:831–4.
- 3 Institute of Medicine. Institute of Medicine Committee on the Quality of Health Care in America. *Crossing the Quality Chasm: A New Health System for the 21st Century*. Washington, DC, National Academy Press, 2001.
- 4 de Vries TPGM, Henning RH, Hogerzeil HV, Fresle DA. WHO Guide to Good Prescribing – A Practical Manual. Available from: <http://apps.who.int/medicinedocs/pdf/whozip23e/whozip23e.pdf> (last accessed 18 November 2015).
- 5 Agency for Healthcare Research and Quality. National Quality Measure Clearinghouse. Available from: <http://www.qualitymeasures.ahrq.gov/> (last accessed 18 November 2015).
- 6 Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. *New England Journal of Medicine*. 2011;**365**:2002–12.
- 7 Martirosyan L, Voorham J, Haaijer-Ruskamp FM, Braspenning J, Wolffenbuttel BH, Denig P. A systematic literature review: prescribing indicators related to type 2 diabetes mellitus and cardiovascular risk management. *Pharmacoepidemiology & Drug Safety*. 2010;**19**:319–34.
- 8 HRSA Health Disparities Collaboratives: Diabetes Collaborative. Available from: <http://www.qualitymeasures.ahrq.gov/browse/by-organization-indiv.aspx?orgid=1798> (last accessed 18 November 2015).
- 9 Australian Institute of Health and Welfare. Towards National Indicators of Safety and Quality in Health Care. Available from: <http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=6442457172> (last accessed 18 November 2015).
- 10 British Medical Association. England QOF Guidance 7th Revision 2014–2015. Available from: <http://downloadmp3.site/download/bma-qof-guidance-latest-revision-british-medical-> (last accessed 18 November 2015).
- 11 National Quality Forum. National Voluntary Consensus Standards for Ambulatory Care Using Clinically Enriched Administrative Data. —Available from: http://www.qualityforum.org/projects/ambulatory_clinically_enriched_data.aspx (last accessed 18 November 2015).
- 12 Voorham J, Haaijer-Ruskamp FM, van der Meer K, de Zeeuw D, Wolffenbuttel BH, Hoogenberg K, Denig P; GIANTT-Group. Identifying targets to improve treatment in type 2 diabetes; the Groningen Initiative to ANalyse Type 2 diabetes Treatment (GIANTT) observational study. *Pharmacoepidemiology & Drug Safety*. 2010;**19**:1078–86.
- 13 Groningen Initiative to ANalyse Type 2 diabetes Treatment. Spiegelinformatie voorbeeld test praktijk [Sample General Practitioner Feedback Information]. Available from: http://giantt.nl/bm_311.pdf (last accessed 18 November 2015).
- 14 O'Connor PJ, Bodkin NL, Fradkin J, Glasgow RE, Greenfield S, Gregg E, et al. Diabetes performance measures: current status and future directions. *Diabetes Care*. 2011;**34**:1651–9. Erratum in: *Diabetes Care*. 2011;**34**:2631.
- 15 Guthrie B, Inkster M, Fahey T. Tackling therapeutic inertia: role of treatment data in quality indicators. *British Medical Journal*. 2007;**335**(7619):542–4.

- 16 Drozda J, Messer JV, Spertus J. ACCF/AHA/AMA-PCPI 2011 performance measures for adults with coronary artery disease and hypertension: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and the American Medical Association-Physician Consortium for Performance Improvement. *Journal of the American College of Cardiology*. 2011;58:316–36.
- 17 Luehr D, Woolley T, Burke R, Dohmen F, Hayes R, Johnson M, et al.; Institute for Clinical Systems Improvement. Hypertension Diagnosis and Treatment. Available from: https://www.icsi.org/_asset/wjyqy4g/HTN.pdf (last accessed 18 November 2015).
- 18 de Vries ST, Voorham J, Haaijer-Ruskamp FM, Denig P. Potential overtreatment and undertreatment of diabetes in different patient age groups in primary care after the introduction of performance measures. *Diabetes Care*. 2014;37:1312–20.
- 19 Sidorenkov G, Haaijer-Ruskamp FM, de Zeeuw D, Denig P. A longitudinal study examining adherence to guidelines in diabetes care according to different definitions of adequacy and timeliness. *PLoS ONE*. 2011;6:e24278.
- 20 Voorham J, Denig P, Wolffenbuttel BH, Haaijer-Ruskamp FM. Cross-sectional versus sequential quality indicators of risk factor management in patients with type 2 diabetes. *Medical Care*. 2008;46:133–41.
- 21 Sidorenkov G, Voorham J, Haaijer-Ruskamp FM, de Zeeuw D, Denig P. Association between performance measures and glycemic control among patients with diabetes in a community-wide primary care cohort. *Medical Care*. 2013;51:172–9.
- 22 Sidorenkov G, Voorham J, de Zeeuw D, Haaijer-Ruskamp FM, Denig P. Treatment quality indicators predict short term outcomes in diabetes patients: a prospective cohort study using the GIANTT database. *British Medical Journal Quality & Safety*. 2013;22:339–47.
- 23 Kerr EA, Lucatorto MA, Holleman R, Hogan MM, Klamerus ML, Hofer TP, et al. Monitoring performance for blood pressure management among patients with diabetes mellitus: too much of a good thing? *Archives of Internal Medicine*. 2012;172:938–45.
- 24 Choe HM, Bernstein SJ, Standiford CJ, Hayward RA. New diabetes HEDIS blood pressure quality measure: potential for overtreatment. *American Journal of Managed Care*. 2010;16:19–24.
- 25 Pogach L, Aron D. The other side of quality improvement in diabetes for seniors: a proposal for an overtreatment glycemic measure. *Archives of Internal Medicine*. 2012;172:1510–12.
- 26 Handberg E. How do guidelines impact measures of performance? Can they keep up? *Archives of Internal Medicine*. 2012;172:945–6.
- 27 Sidorenkov G, Haaijer-Ruskamp FM, de Zeeuw D, Bilo HJG, Denig P. Review: relation between quality-of-care indicators for diabetes and patient outcomes: a systematic literature review. *Medical Care Research and Review*. 2011;68:263–89.
- 28 Ashworth M, Golding S, Majeed A. Prescribing indicators and their use by primary care groups to influence prescribing. *Journal of Clinical Pharmacology & Therapeutics*. 2002;27:197–04.
- 29 Norman C, Zarrinkoub R, Hasselström J, Godman B, Granath F, Wettermark B. Potential savings without compromising the quality of care. *International Journal of Clinical Practice*. 2009;63:1320–6.
- 30 Muijers PE, Janknegt R, Sijbrandij J, Grol RP, Knottnerus JA. Prescribing indicators. Development and validation of guideline-based prescribing indicators as an instrument to measure the variation in the prescribing behaviour of general practitioners. *European Journal of Clinical Pharmacology*. 2004;60:739–46.
- 31 MacKinnon NJ, Hartnell NR, Black EK, Dunbar P, Johnson J, Halliday-Mahar S, et al. Development of clinical indicators for type 2 diabetes. *Canadian Pharmacists Journal*. 2009;141:120–8.
- 32 Dreischulte T, Grant AM, McCowan C, McAnaw JJ, Guthrie B. Quality and safety of medication use in primary care: consensus validation of a new set of explicit medication assessment criteria and prioritization of topics for improvement. *BMC Clinical Pharmacology*. 2012;12:5.
- 33 Bally K, Buechel RR, Buser P, Tschudia P, Martinaa B, Zeller A. Discontinuation of secondary prevention medication after myocardial infarction – the role of general practitioners and patients. *Swiss Medical Weekly*. 2013;143:w13896.
- 34 American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate

- medication use in older adults. *Journal of the American Geriatric Society*. 2012;**60**:616–31.
- 35 Jano E, Aparasu RR. Healthcare outcomes associated with Beers' criteria: a systematic review. *Annals of Pharmacotherapy*. 2007;**41**:438–47.
 - 36 Albert SM, Colombi A, Hanlon J. Potentially inappropriate medications and risk of hospitalization in retirees: analysis of a US retiree health claims database. *Drugs & Aging*. 2010;**27**:407–15.
 - 37 National Committee for Quality Assurance. HEDIS 2013: Healthcare Effectiveness Data and Information Set. Vol. 1, Narrative. Available from: <http://www.ncqa.org/HEDISQualityMeasurement/HEDISMeasures/HEDIS2013.aspx> (last accessed 18 November 2015).
 - 38 Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C, Hanlon JT. Appropriate prescribing in elderly people: how well can it be measured and optimized? *Lancet*. 2007;**370**(9582):173–84.
 - 39 Levy HB, Marcus EL, Christen C. Beyond the Beers criteria: a comparative overview of explicit criteria. *Annals of Pharmacotherapy*. 2010;**44**:1968–75.
 - 40 Holt S, Schmiedl S, Thürmann PA. Potentially inappropriate medications in the elderly: the PRISCUS list. *Deutsches Ärzteblatt International*. 2010;**107**(31–2):543–51.
 - 41 Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D. STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. *International Journal of Clinical Pharmacology & Therapeutics*. 2008;**46**:72–83.
 - 42 Hill-Taylor B, Sketris I, Hayden J, Byrne S, O'Sullivan D, Christie R. Application of the STOPP/START criteria: a systematic review of the prevalence of potentially inappropriate prescribing in older adults, and evidence of clinical, humanistic and economic impact. *Journal of Clinical Pharmacology & Therapeutics*. 2013;**38**:360–72.
 - 43 Hamilton H, Gallagher P, Ryan C, Byrne S, O'Mahony D. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. *Archives of Internal Medicine*. 2011;**171**:1013–19.
 - 44 O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. *Age & Ageing*. 2015;**44**(2):213–18.
 - 45 Ryan C, O'Mahony D, O'Donovan DO, O'Grady E, Weedle P, Kennedy J, Byrne S. A comparison of the application of STOPP/START to patients' drug lists with and without clinical information. *International Journal of Clinical Pharmacy*. 2013;**35**:230–5.
 - 46 Shrank WH, Polinski JM, Avorn J. Quality indicators for medication use in vulnerable elders. *Journal of the American Geriatric Society*. 2007;**55**(Suppl. 2):S373–82.
 - 47 Rand Health. Quality Indicators – ACOVE 3. Available from: <http://www.rand.org/health/projects/acove/acove3.html> (last accessed 18 November 2015).
 - 48 Avery AJ, Dex GM, Mulvaney C, Serumaga B, Spencer R, Lester HE, Campbell SM. Development of prescribing-safety indicators for GPs using the RAND appropriateness method. *British Journal of General Practice*. 2011;**61**:e526–36.
 - 49 Hilmer SN, Mager DE, Simonsick EM, Cao Y, Ling SM, Windham BG, et al. A drug burden index to define the functional burden of medications in older people. *Archives of Internal Medicine*. 2007;**167**(8):781–7.
 - 50 Hilmer SN, Gnjjidic D. The effects of polypharmacy in older adults. *Clinical Pharmacology & Therapeutics*. 2009;**85**:86–8.
 - 51 Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. *British Journal of Clinical Pharmacology*. 2007;**63**:187–95.
 - 52 Ivers N, Jamtvedt G, Flottorp S, Young JM, Odgaard-Jensen J, French SD, et al. Audit and feedback: effects on professional practice and healthcare outcomes. *Cochrane Database of Systematic Reviews*. 2012;**6**:CD000259.
 - 53 Health & Social Care Information Centre. Prescribing. Available from: <http://www.hscic.gov.uk/Article/1689> (last accessed 18 November 2015).
 - 54 Dutch Institute for Rational Use of Medicine website: <http://www.medicijngebruik.nl/ondersteuning-fto/verbeteren-voorschrijfgedrag>.
 - 55 van den Berg MJ, Kringos DS, Marks LK, Klazinga NS. The Dutch health care performance report: seven years of health care performance assessment in the Netherlands. *Health Research Policy and Systems*. 2014;**12**:1.
 - 56 World Health Organization. How to Investigate Drug Use in Health Facilities: Selected Drug Use Indicators – EDM Research Series No. 007. Available from:

- <http://apps.who.int/medicinedocs/en/d/Js2289e/> (last accessed 18 November 2015).
- 57** Goossens H, Ferech M, Vander Stichele R, Elseviers M; ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. *Lancet*. 2005;**365**:579–87.
- 58** Adriaenssens N, Coenen S, Tonkin-Crine S, Verheij TJ, Little P, Goossens H; on behalf of the ESAC Project Group. European Surveillance of Antimicrobial Consumption (ESAC): disease-specific quality indicators for outpatient antibiotic prescribing. *British Medical Journal Quality & Safety*. 2011;**20**:764–72.
- 59** Campbell SM, Reeves D, Kontopantelis E, Sibbald B, Roland M. Effects of pay-for-performance on the quality of primary care in England. *New England Journal of Medicine*. 2009;**361**(4):368–78.
- 60** Integrated Healthcare Association. Measurement Year 2014. Available from: http://www.iha.org/manuals_operations_2014.html (last accessed 18 November 2015).
- 61** Shekelle PG. Quality indicators and performance measures: methods for development need more standardization. *Journal of Clinical Epidemiology*. 2013;**66**:1338–9.